AURORA Trial Voclosporin — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

HardSLE & Antiphospholipid SyndromeAURORA Trial VoclosporinSCE Rheumatology

A 42-year-old woman with SLE asks about the AURORA-1 trial. What did it establish?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Voclosporin added to standard MMF and low-dose steroid improved complete renal response at 52 weeks for lupus nephritis

AURORA-1 showed 41% vs 23% complete renal response with Voclosporin add-on. Voclosporin is a next-generation CNI not requiring TDM. EULAR 2023 includes it as add-on option.

Reference: Rovin BH et al 2021 AURORA-1 Lancet